Search results
22 maj 2023 · Bullous systemic lupus erythematosus (BSLE) is a rare manifestation of systemic lupus erythematosus. It has clinical and histological features that may lead to misdiagnosis and delayed treatment of this easily treatable condition.
8 lis 2023 · Bullous SLE is rare blistering disorder characterized by subepidermal blisters. We, hereby, present a case of bullous SLE in a 24-year-old female who responded well to systemic glucocorticoids, mycophenolate mofetil, and dapsone.
What is the treatment for bullous systemic lupus erythematosus? Dapsone, at a dose of 1.0–1.5 mg/kg/day, is considered the treatment of choice. It is effective in the vast majority of patients and leads to rapid clinical improvement within days or a few weeks.
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus ery-thematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
31 paź 2014 · Clinically similar to bullous pemphigoid (BP), linear IgA bullous dermatosis, epidermolysis bullosa acquisita (EBA), and dermatitis herpetiformis (DH), it is important for physicians to consider BSLE when confronted with a bullous skin eruption.
25 lut 2019 · BSLE is a rare blistering disease that mainly occurs in females (30–40 years old), and less frequently in children and adolescents. The most common presentation is rapid and widespread development of tense vesicles and bullae over erythematous macules or plaques.
7 paź 2021 · Pharmacologic Therapy. Dapsone is the initial treatment of choice for bullous systemic lupus erythematosus. [2, 34] The response is usually dramatic, with cessation of new blister formation...
